Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson Sells 4,727 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 4,727 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $34,601.64. Following the transaction, the general counsel now directly owns 135,528 shares of the company’s stock, valued at $992,064.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA traded down $0.20 during trading on Tuesday, reaching $7.24. The company had a trading volume of 79,534 shares, compared to its average volume of 175,932. The firm’s fifty day moving average is $7.41 and its 200 day moving average is $7.68. The firm has a market capitalization of $241.59 million, a PE ratio of -7.31 and a beta of 1.04. Sera Prognostics, Inc. has a twelve month low of $1.65 and a twelve month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the previous year, the company posted ($0.23) EPS. Equities analysts predict that Sera Prognostics, Inc. will post -0.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds have recently made changes to their positions in the company. Quest Partners LLC boosted its position in Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the period. SG Americas Securities LLC bought a new position in Sera Prognostics during the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics during the 2nd quarter worth approximately $68,000. Prime Capital Investment Advisors LLC acquired a new stake in Sera Prognostics in the 3rd quarter valued at $104,000. Finally, Lake Street Advisors Group LLC bought a new stake in shares of Sera Prognostics during the 2nd quarter worth $144,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.